Soleno Therapeutics Inc SLNO
We take great care to ensure that the data presented and summarized in this overview for SOLENO THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SLNO
Top Purchases
Top Sells
About SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Insider Transactions at SLNO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 01
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
3,830
-22.48%
|
$314,060
$82.76 P/Share
|
|
Jun 24
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
266
-1.54%
|
$22,344
$84.25 P/Share
|
|
Jun 24
2025
|
Patricia C Hirano |
BUY
Exercise of conversion of derivative security
|
Direct |
266
+1.51%
|
$11,704
$44.25 P/Share
|
|
Jun 05
2025
|
Andrew Sinclair |
BUY
Grant, award, or other acquisition
|
Direct |
3,991
+27.56%
|
-
|
|
Jun 05
2025
|
Birgitte Volck |
BUY
Grant, award, or other acquisition
|
Direct |
3,991
+18.54%
|
-
|
|
Jun 05
2025
|
William G Harris |
BUY
Grant, award, or other acquisition
|
Direct |
3,991
+17.07%
|
-
|
|
Jun 05
2025
|
Matthew Pauls |
BUY
Grant, award, or other acquisition
|
Direct |
3,991
+27.56%
|
-
|
|
Jun 05
2025
|
Dawn Carter Bir |
BUY
Grant, award, or other acquisition
|
Direct |
3,991
+19.02%
|
-
|
|
Apr 01
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
3,782
-12.27%
|
$264,740
$70.11 P/Share
|
|
Mar 28
2025
|
Matthew Pauls |
SELL
Open market or private sale
|
Direct |
5,937
-47.74%
|
$421,527
$71.55 P/Share
|
|
Mar 28
2025
|
Matthew Pauls |
BUY
Exercise of conversion of derivative security
|
Direct |
5,937
+32.31%
|
$23,748
$4.6 P/Share
|
|
Mar 28
2025
|
Patricia C Hirano |
SELL
Open market or private sale
|
Direct |
27,662
-14.46%
|
$1,908,678
$69.87 P/Share
|
|
Mar 28
2025
|
Patricia C Hirano |
BUY
Exercise of conversion of derivative security
|
Direct |
2,691
+4.4%
|
$88,803
$33.6 P/Share
|
|
Mar 28
2025
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
333,557
-6.96%
|
$23,348,990
$70.6 P/Share
|
|
Mar 27
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
90,622
-5.78%
|
$6,252,918
$69.46 P/Share
|
|
Mar 27
2025
|
James H Mackaness CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+8.63%
|
$630,000
$9.22 P/Share
|
|
Mar 27
2025
|
Meredith Manning Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
45,249
-6.82%
|
$3,122,181
$69.03 P/Share
|
|
Mar 27
2025
|
Meredith Manning Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+31.0%
|
$1,702,000
$46.31 P/Share
|
|
Mar 27
2025
|
Kristen Yen |
SELL
Open market or private sale
|
Direct |
95,500
-12.43%
|
$6,494,000
$68.71 P/Share
|
|
Mar 27
2025
|
Kristen Yen |
BUY
Exercise of conversion of derivative security
|
Direct |
40,638
+11.97%
|
$162,552
$4.25 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.33M shares |
|---|---|
| Exercise of conversion of derivative security | 762K shares |
| Open market or private sale | 4.36M shares |
|---|